Nang Kuang Pharmaceutical Co (TPE:1752) Earnings Power Value (EPV): NT$2.97 (As of Dec25)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1752 Nang Kuang Pharmaceutical Co Ltd TPE:1752
88 GF Score
Price NT$31.35
GF Value NT$46.62
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Nang Kuang Pharmaceutical Co Earnings Power Value (EPV)?

Nang Kuang Pharmaceutical Co TPE:1752 -1.10% 88 Earnings Power Value (EPV) is NT$2.97 as of Dec25. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review.

As of Dec25, Nang Kuang Pharmaceutical Co's earnings power value is NT$2.97. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is -955.87

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Nang Kuang Pharmaceutical Co  (TPE:1752) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Nang Kuang Pharmaceutical Co Earnings Power Value (EPV) Related Terms


Nang Kuang Pharmaceutical Co Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nang Kuang Pharmaceutical Co Earnings Power Value (EPV) Chart

Nang Kuang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.88 16.82 15.00 5.08 2.97

Nang Kuang Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.08 6.15 3.22 2.02 2.97

TPE:1752 vs ISRG, BDX, MDLN: Earnings Power Value (EPV) Comparison

For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nang Kuang Pharmaceutical Co Earnings Power Value (EPV) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV) falls into.


TPE:1752
88GF Score
Nang Kuang Pharmaceutical Co Ltd TPE:1752
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nang Kuang Pharmaceutical Co Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Nang Kuang Pharmaceutical Co's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 2,047
DDA 181
Operating Margin % 14.71
SGA * 25% 63
Tax Rate % 19.45
Maintenance Capex 256
Cash and Cash Equivalents 351
Short-Term Debt 470
Long-Term Debt 186
Shares Outstanding (Diluted) 101

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = 14.71%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = NT$2,047 Mil, Average Operating Margin = 14.71%, Average Adjusted SGA = 63,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 2,047 * 14.71% +63 = NT$363.963681316 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 19.45%, and "Normalized" EBIT = NT$363.963681316 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 363.963681316 * ( 1 - 19.45% ) = NT$293.15818675279 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 181 * 0.5 * 19.45% = NT$17.588127952 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 293.15818675279 + 17.588127952 = NT$310.74631470479 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Nang Kuang Pharmaceutical Co's Average Maintenance CAPEX = NT$256 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Nang Kuang Pharmaceutical Co's current cash and cash equivalent = NT$351 Mil.
Nang Kuang Pharmaceutical Co's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 186 + 470 = NT$655.953 Mil.
Nang Kuang Pharmaceutical Co's current Shares Outstanding (Diluted Average) = 101 Mil.

Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV) for Dec25 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 310.74631470479 - 256)/ 9%+351-655.953 )/101
=2.97

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( 2.9691270057796-31.35 )/2.9691270057796
= -955.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of NT$2.97 mean?
Nang Kuang Pharmaceutical Co (TPE:1752) has a Earnings Power Value (EPV) of NT$2.97 as of Dec25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Nang Kuang Pharmaceutical Co and its competitors.
Is Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV) too high?
Nang Kuang Pharmaceutical Co's current Earnings Power Value (EPV) is NT$2.97. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV) compare to ISRG and BDX?
Nang Kuang Pharmaceutical Co's Earnings Power Value (EPV) of NT$2.97 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Medical Devices & Instruments company?
A good Earnings Power Value (EPV) depends on the Medical Devices & Instruments industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Nang Kuang Pharmaceutical Co and its competitors. Nang Kuang Pharmaceutical Co's current Earnings Power Value (EPV) is NT$2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current Earnings Power Value (EPV) is NT$2.97. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current Earnings Power Value (EPV) is NT$2.97 as of Dec25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?

Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62. GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for TPE:1752:

  • Earnings Power Value (EPV): NT$2.97
  • GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nang Kuang Pharmaceutical Co Business Description

Address Section 8, Civic Boulevard, 5th Floor, No. 205, Nangang District, Taipei, TWN, 115
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score

Get the complete analysis for TPE:1752

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.35
Price
NT$46.62
GF Value